May. 21, 2019News & Opinions
Novartis may be close to a billion-dollar settlement with the US government to resolve a whistleblower lawsuit accusing the Swiss pharmaceuticals giant of bribing doctors to boost prescriptions of its drugs.
May. 17, 2019News & Opinions
US protein engineering company Codexis has signed a platform agreement with Novartis, granting the Swiss pharmaceutical producer a non-exclusive license to its proprietary CodeEvolver protein technology.
May. 13, 2019News & Opinions
To lighten its debt burden of more than $30 billion resulting from last year’s acquisition of Shire, Japanese pharma giant Takeda is selling Shire’s dry-eye drug Xiidra to Switzerland’s Novartis.
Apr. 17, 2019News & Opinions
Swiss drugmaker Novartis and US biopharma Amgen are embroiled in a legal dispute regarding their collaboration on migraine prevention drug Aimovig.
Apr. 08, 2019Topics
The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs ...
Apr. 03, 2019News & Opinions
Swiss drugmaker Novartis has agreed to buy US biotech IFM Tre in a deal worth nearly $1.6 billion, boosting its portfolio of anti-inflammatory medicines. Novartis will pay $310 million upfront with IFM eligible to receive up to ...
Mar. 05, 2019News & Opinions
Novartis’ ill-advised attempt two years ago to get an inside look at drugs pricing policies of newly elected US president Donald Trump came back to haunt it last week during the hearing of former presidential lawyer Michael ...
Nov. 19, 2018News & Opinions
After completing a portfolio review, Novartis has dropped around 20% of its R&D projects as it narrows its focus to the most cutting-edge medicines. Jay Bradner, president of the Novartis Institutes for Biomedical Research, said ...
Oct. 18, 2018News & Opinions
Novartis has agreed to buy US biopharma Endocyte, gaining access to radiopharmaceuticals, which the Swiss drugmaker has identified as a key growth driver of its business.
Sep. 27, 2018News & Opinions
Drugmaker Novartis has announced plans to cut around 2,200 jobs in Switzerland and exit its site in Grimsby, UK, as it transforms its global manufacturing network and product portfolio.
The latest information directly via newsletter.